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Background: Acupuncture is safe and may be effective for severe chronic constipation. The World
Gastroenterology Organisation recommends prucalopride for patients for whom previous laxative use failed to
provide satisfactory relief.
Methods/design: In this prospective, multi-centre, randomised controlled trial, five hundred sixty patients with
severe chronic constipation (two or less spontaneous complete bowel movements per week) from 14 centres will
be randomised to receive either electroacupuncture or prucalopride. Participants in the electroacupuncture group
will receive electroacupuncture for eight weeks, while participants in the control group will take prucalopride
(2 mg once daily) for 32 weeks. The primary outcome measure is the proportion of patients having ≥3 spontaneous,
complete bowel movements per week, averaged over week three to eight. The secondary outcome measures include
eight items, including the proportion of patients having ≥3 spontaneous, complete bowel movements per week
averaged over week 9–32, the proportion of patients with one or more increases in spontaneous, complete bowel
movements per week from baseline, mean Bristol Stool Scale, etc. Statistical analysis will include the CMH test,
nonparametric tests and t tests.
Discussion: We aimed to compare the effect of electroacupuncture versus prucalopride for severe chronic
constipation. The limitation of this study is that participants and acupuncturists will not be blinded.
Trial registration: ClinicalTrials.gov Identifier: NCT 02047045.
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Twelve percent of adults have constipation worldwide [1].
In China, the figure is 4%-6% [2,3]. Severe chronic consti-
pation is defined as two or fewer spontaneous, complete
bowel movements (SCBMs) per week, hard stool and a
sensation of straining during defecation [4]. Due to their
widespread use, laxatives are an available choice for con-
stipated patients. However, a high level of dissatisfaction
has been reported for laxatives; specifically, evidence sup-
porting the lasting effect of laxatives is limited [5-7]. A* Correspondence: liuzhishun@aliyun.com
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unless otherwise stated.study of PEG3350 showed that 38.4 ± 14.1 days after the
cessation of PG3350, 29 of 47 (61.7%) patients needed to
take additional constipation treatment interventions [8]. A
survey of 744 patients with chronic constipation in Europe
showed that almost half were using alternative treatments
(homeopathy, massage and acupuncture), and nearly 90%
of respondents expressed interests in new therapies [6].
With a history of thousands of years, acupuncture has
long been used to treat constipation in China. The system-
atic review [9] we have published concluded that acupunc-
ture was safe for chronic functional constipation and might
improve weekly spontaneous bowel movements (SBMs),
the quality of life, and relevant symptoms. However, the
evidence was limited by the small sample size and theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ished showed that 31.67% patients had 3 or more weekly
SBMs after 8 weeks of treatment. By the third month, 40%
patients still had 3 or more weekly SBMs, which reflected
the lasting effect (effect post treatment) of acupuncture (to
be published).
This report is a protocol of a phase-II trial aiming
to evaluate the effect of electroacupuncture (EA) versus
prucalopride for severe chronic constipation. The World
Gastroenterology Organisation recommends prucalopride
for patients for whom previous laxative use failed to pro-
vide satisfactory relief [10]. It was also considered effective
and safe in a randomised controlled trial conducted in the
Asia-Pacific region [11]. Thus, the use of prucalopride as
the control drug in this trial is reasonable. The objective is
to compare the effect of EA versus prucalopride for severe
chronic constipation. We will also observe how many pa-
tients will not need additional medicine until the 3rd and
6th month post treatment. The safety and acceptance of
EA will be simultaneously evaluated.Figure 1 The flowchart.Methods/design
Study design
This study is a prospective randomised controlled trial. It
will be conducted from April 2014 to August 2015 at 14
hospitals around Chinaa. Five hundred and sixty partici-
pants are planned to be recruited via advertisements in
newspapers, television, websites and posters. After being di-
agnosed by physicians of the gastroenterology or anorectal
departments, participants will receive a 2-week long assess-
ment (the stool diary). Randomisation will be performed
centrally by the Clinical Evaluation Centre of the China
Academy of Chinese Medical Sciences in Beijing, and eli-
gible participants will be randomised into the EA group or
the control group. After the baseline assessment has been
carried out and the informed consent has been obtained, a
randomisation number will be sent to the acupuncturist by
phone or online. The statisticians, outcome assessors, and
physicians will be blinded to the allocation. The flowchart
of the trial is presented in Figure 1. The duration of
the trial is 34 weeks, including a 2-week long baseline
Liu et al. BMC Complementary and Alternative Medicine 2014, 14:260 Page 3 of 6
http://www.biomedcentral.com/1472-6882/14/260assessment period (week-2-0), 8-week long treatment
period (week 1–8), and 24-week long follow-up period
(week 9–32). The time frame of the trial is presented in
Figure 2. The trial protocol is in accordance with the
principles of the Declaration of Helsinki and has been
approved by the review board and ethics committee of
the participating hospitals.
Participants
Five hundred and sixty participants met the Rome III
criteria [12] are planned to be recruited.
Inclusion criteria: 1) Primary chronic constipation meet-
ing the Rome III criteria, with ≤2 SCBMs (SCBM refers to
the feeling of complete evacuation after a bowel move-
ment without the help of drug or hands in the past
24 hours. Bowel movement beyond 24 hours after the use
of medicine/hands also could be considered a SCBM).
They should conform to at least one of the following items
at the same time: a. a feeling of straining during evacu-
ation (at least once per 4 bowel movements); b. lumpy or
hard stools (at least once per 4 bowel movements); c. a
feeling of incomplete evacuation after a bowel movement
(at least once per 4 bowel movements); d. a feeling of ob-
struction in the anus/rectum (at least once per 4 bowel
movements); e. needing the help of hands for evacuation
(at least once per 4 bowel movements). 2) Participants
who do not meet the diagnosis of irritable bowel syn-
drome (IBS). 3) Previous laxative use failed to provide sat-
isfactory relief. 4) Patients aged 18 to 75 years old. 5) Two
or fewer SBMs per week during the 2-week long baseline
assessment. 6) No use of medicine for constipation during
the 2 weeks before enrolment (except rescue medication
usage); no acupuncture treatment for constipation in the
previous 1 month; no participation in any other on-going
trial. 7) Volunteered to join this trial and signed the in-
formed consent.
Exclusion criteria: 1) Irritable bowel syndrome, organic
constipation or secondary constipation caused by endo-
crine, metabolic, nervous, postoperative diseases, or drugs;
2) More than one mushy or watery stool during baseline
while not taking laxatives (Bristol stool type 6 or 7); 3) A
history of pelvic floor dysfunction; 4) Taking medicine that
can influence the intestinal function or induce constipa-
tion; 5) Severe haemorrhoid or anal fissure; 6) Patients
with severe cardiovascular, hepatic or renal diseases, cog-
nitive impairment, abdominal aortic aneurysm or hepatos-
plenomegaly, aphasia, mental disorders, or illness that willFigure 2 Time Frame of the Trial.influence the examination or treatment; 7) Women in the
gestation or lactation period; 8) Patients with blood coagu-
lation disorders or taking anticoagulants regularly, such as
Warfarin and Heparin; 9) Patients with a cardiac pace-
maker carrier.
Intervention
All participants will be advised of lifestyle modification,
such as maintaining their original lifestyle, avoiding fibre-
rich food or following a weight-loss diet. Therapies other
than the treatment regimen are prohibited during the trial.
Treatment group
The acupuncture regimen is based on the Chinese litera-
ture from the past 20 years, our pilot trial and specialist
consensus. The point regimen (points used for every
participants of EA group) includes bilateral ST25, SP14
and ST 37. Moreover, BL33, DU20 and DU24 could be
used according to the individual situation. BL 33 could
be used for straining and incomplete evacuation. DU20
and DU24 could be used for anxiety and depression.
For ST25 and SP14, the needle will be inserted vertically
to the abdominal muscles. The acupuncturist can feel re-
sistance from the tip of the needle when touching the
muscles and continues to insert it to a depth of 2–3 mm
and stops. For ST 37, the needle will be inserted vertically
to a depth of 25 mm. The needle will be manipulated with
an even lifting and twisting method three times to achieve
the sensation of deqi (patients having a sour and disten-
sion sensation). For DU20 and DU24, the needle is ob-
liquely inserted back towards the galea aponeurotica to a
depth of 40 mm. The needle is manipulated with an even
lifting and twisting method three times to achieve the sen-
sation of deqi. If BL33 is needed, all points could be simul-
taneously needled when participants are in the lateral
decubitus position. The site 0.5-1 cm outside and above
the 3rd posterior sacral foramina will serve as the inserting
site. The needle is inserted at the inserting site inward
and downward at a 30–45 degree angle to a depth of
50–60 mm.
An electric stimulator will be placed on the pair of ST25
and SP14 points with a spare-dense wave, 10/50 Hz,
0.1–1.0 mA (for BL33, the intensity is 0.5-2.0 mA). For
ST37, DU20 and DU24, the needles will be manipulated
with an even lifting and twisting method every ten minutes,
and three manipulations will be used for each participant in
all. Patients will be given one session per day for 30 min,
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the next 6 weeks.
Control group
Prucalopride Succinate (Janssen S.P.A) will be taken orally
at a dose of 2 mg/day before breakfast for 8 weeks. Partici-
pants will undergo an electrocardiogram (ECG) at the 8th
week, and the drug will be taken for another 24 weeks in
the absence of adverse events (like Q-T elongation).
The use of other medicine for constipation will not be
allowed during the trial. Bisacodyl (5–10 mg) and Enemia
Glycerini (110 ml) can be used for participants who fail to
have a bowel movement for 3 or more consecutive days.
Furthermore, the use of Bisacodyl and Enemia Glycerini
should be recorded on the case report form.
Outcome measures
The outcome measures are based on the stool diary. The
participants complete a stool diary, which is checked by
outcome assessors and finally recorded in the Remote
Data Capture (RDC) system. The contents of the stool
diary include SBMs within 24 hours, straining degree,
complete evacuation, stool consistency, use of drugs, etc.
Participants will be asked to finish the diaries every day
during the baseline assessment period, week 1–8, 11–12,
15–16, 19–20 and 31–32.
This trial includes one primary outcome measure and 8
secondary outcome measures. The primary outcome is the
proportion of patients having ≥3 SCBMs/week, averaged
over week 3–8. The secondary outcome measures are pre-
sented in Table 1. The safety of EA will be evaluated based
on various events, including fainting, severe pain, haema-
toma, local infection, and any feeling of discomfort. The
side effects of prucalopride include diarrhoea, nausea, ab-
dominal pain, headache, palpitation, myocardial ischemia
(presented in ECG), etc. Any adverse event resulting from
EA or adverse drug reaction will be recorded.Table 1 Secondary outcome measures
No. Outcome measure Time frame
1 Proportion of patients having ≥3 SCBMs/week Week 1–2, w




3 SCBMs/week and change from baseline Week 1–2, w
week 9-32




5 Mean Bristol Stool Scale and change from baseline Baseline, we
6 Straining degree Week 1–2, w
week 9-32
7 Time to first SCBM Time from t
8 Patient assessment of Constipation Quality Of Life
(PAC-QOL)
Baseline, weData collection and quality control
Two researchers will independently input the data using
the Remote Data Capture (RDC) software. A DataVerifica-
tion Plan (DVP) will be established to review the data after
input. Two data managers with a medical background will
code the medical history, adverse events and drug combi-
nations. After a data review, the data will be submitted to
the statistician for final analysis.
A rigorous methodology will be followed to guarantee
the quality of the trial. Before commencing the trial, experts
in different fields will be invited to review and revise the
protocol, and staff from the 14 trial centres will undergo
training. A 3-level monitoring system will be established to
periodically assess the performance of the trial. The out-
come assessments, the completion of case report forms
and data management will be closely supervised.
Sample size and statistical analysis
The sample size will be based on the primary outcome
(the proportion of patients having ≥3 SCBMs/week aver-
aged over week 3–8). According to our pilot trial and
the literature [4], the proportion of participant having ≥3
SCBMs averaged over week 3–8 was 31.6% for the EA
group and 30.9% for the prucalopride group. The figure for
the placebo group was 12.0% [4]. Thus, a non-inferiority
margin of 10% is reasonable. To assess the non-inferiority
between the treatment and control groups, a sample size
of 276 for each group will be sufficient, with a one-sided
5% level of significance, a power of 80% and allowing for a
20% dropout. In this trial, we aim to recruit 560 partici-
pants, 40 for each hospital.
The data from the 14 centres will be pooled, and the
Clinical Evaluation Centre of the China Academy of
Chinese Medical Sciences in Beijing will conduct the statis-
tical analysis using the SAS 9.1.3 (SAS Institute, Cary, NC,
US) and SPSS Ver.13.0 (SPSS Inc., Chicago, IL, USA) soft-
ware. The data analysis is based on the intention-to-treatStatistics
eek 9–12, week 9–16, week 9–20, week 9-32 CMH test
eek 3–8, week 9–12, week 9–16, week 9–20, CMH test
eek 3–8, week 9–12, week 9–16, week 9–20, Nonparametric test
eek 3–8, week 9–12, week 9–16, week9-20, Nonparametric test
ek 1–2, week 3-8 Nonparametric test
eek 3–8, week 9–12, week 9–16, week 9–20, Nonparametric test
he first treatment to the first SCBM Nonparametric test
ek 1–4, week 5-8 t test or Mann–Whitney
U test
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tests except for the primary outcome. The level of signifi-
cance will be established at 0.05. Continuous data will be
represented by the mean, standard deviation, median, mini-
mum value, and maximum value; categorical data will be
represented by percentages. To compare two independent
samples, a t-test or nonparametric test will be used for
continuous data, and a chi-square test/the Fisher exact
test/nonparametric tests will be used for categorical data.
For the primary outcome, the CMH test will be used to
avoid the centre effect. The analysis methods for second-
ary outcomes are presented in Table 1. For safety analysis,
the incidence of adverse events will be compared between
the two groups using the chi-square test or the Fisher
exact test.
Discussion
Acupuncture has been used to treat constipation in
China for thousands of years. Clinical practice and sev-
eral trials showed that acupuncture is effective for con-
stipation [13,14]. However, the effect of acupuncture on
severe constipation has not been evaluated. A protocol
of EA versus sham acupuncture for severe constipation
has been published [15].
This is a study design for a non-inferiority, randomised
controlled trial aimed to compare the short-term effect
(the 3rd to 8th treatment week) of EA with prucalopride for
severe chronic constipation. Acupuncture is a non-toxic,
economical intervention with minimal adverse effects [16].
If the efficacy of EA is non-inferior to prucalopride, it may
be a reasonable option for patients who do not want to ex-
perience the side effects of prucalopride. We also want to
observe EA’s lasting effect, i.e., EA’s effect at the 3rd and 6th
month post treatment. The EA group will be treated for
8 weeks and the prucalopride group will be treated for
32 weeks. A comparison between the two groups after
the 8th week could clarify the lasting and dominant ef-
fect of EA.
This trial was limited because the participants and
acupuncturists could not be blinded. However, the out-
come assessors and statistician will be blinded to the
allocation.
In conclusion, the trial will compare the effect of EA
to that of prucalopride for severe chronic constipation.
Trial status
Nineteen participants have been recruited.
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